Persistent changes in gene expression may mediate many alcohol effects including reward learning, tolerance and dependence, suggesting that agents effective at changing alcohol-induced gene expression should be considered as therapeutic agents. Drugs targeting gene expression through inhibition of enzymes that regulate chromatin structure (epigenetic drugs) have been widely used in cancer research and recently emerged as potential therapeutics for neurodegenerative disorders and drug addiction. The main goals of this project are: 1) to identify epigenetic drugs that affect alcohol reward through testing their effects on alcohol consumption and conditioned place preference (CPP) and 2) to investigate the effects of selected epigenetic drugs on gene expression and cellular physiology in the reward pathway including ventral tegmental area (VTA) and the nucleus accumbens (NA). The overall hypothesis is that some epigenetic drugs will reduce the rewarding properties of alcohol through changes in gene expression and cellular physiology in the reward pathway. To address this research problem, we will use a combination of pharmacological, behavioral, genomic and electrophysiological approaches. Alcohol will be delivered via voluntary consumption using a mouse model of binge drinking or via systemic injections to produce CPP. Epigenetic drugs will be delivered via systemic injections prior to alcohol. We will use laser capture microdissections to dissect VTA and NA. We will measure global gene expression in these regions after different combinations of epigenetic drugs, vehicle and alcohol. VTA dopamine neurons will be tested using electrophysiological techniques in parallel with gene expression. Microarray results will be validated using qRT-PCR and epigenetic assays. Integration of electrophysiological and gene expression data will elucidate the drug's mechanisms of action and identify novel targets for drug development. This research will provide initial mechanistic evidence for the therapeutic potential of epigenetic drugs in treating alcohol addiction.
There is clearly a need for more effective and more specific medications for treatment of alcoholism. Epigenetic drugs offer unique advantages in treating diseases through chromatin-dependent changes in gene expression. Completion of this project will provide initial mechanistic evidence for the therapeutic potential of epigenetic drugs in treating alcohol addiction. The ultimate goal of this line of research is to promote the development of new therapies for human alcoholism.
|Ponomarev, Igor; Stelly, Claire E; Morikawa, Hitoshi et al. (2017) Mechanistic insights into epigenetic modulation of ethanol consumption. Alcohol 60:95-101|
|McCarthy, Gizelle M; Warden, Anna S; Bridges, Courtney R et al. (2017) Chronic ethanol consumption: role of TLR3/TRIF-dependent signaling. Addict Biol :|
|Harris, R Adron; Bajo, Michal; Bell, Richard L et al. (2017) Genetic and Pharmacologic Manipulation of TLR4 Has Minimal Impact on Ethanol Consumption in Rodents. J Neurosci 37:1139-1155|
|Cornelison, Garrett L; Daszkowski, Anna W; Pflanz, Natasha C et al. (2017) Interactions between Zinc and Allosteric Modulators of the Glycine Receptor. J Pharmacol Exp Ther 361:1-8|
|Tulisiak, Christopher T; Harris, R Adron; Ponomarev, Igor (2017) DNA modifications in models of alcohol use disorders. Alcohol 60:19-30|
|Mayfield, R Dayne (2017) Emerging roles for ncRNAs in alcohol use disorders. Alcohol 60:31-39|
|Warden, Anna S; Mayfield, R Dayne (2017) Gene expression profiling in the human alcoholic brain. Neuropharmacology 122:161-174|
|Most, Dana; Leiter, Courtney; Blednov, Yuri A et al. (2016) Synaptic microRNAs Coordinately Regulate Synaptic mRNAs: Perturbation by Chronic Alcohol Consumption. Neuropsychopharmacology 41:538-48|
|Marballi, K; Genabai, N K; Blednov, Y A et al. (2016) Alcohol consumption induces global gene expression changes in VTA dopaminergic neurons. Genes Brain Behav 15:318-26|
|Cornelison, Garrett L; Pflanz, Natasha C; Tipps, Megan E et al. (2016) Identification and characterization of heptapeptide modulators of the glycine receptor. Eur J Pharmacol 780:252-9|
Showing the most recent 10 out of 24 publications